EBV EBNA1 TCR-T

EBV EBNA1 TCR-T is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Guangzhou FineImmune Biotechnology. It is designed to target the Epstein-Barr virus nuclear antigen 1 (EBNA1), a protein consistently expressed in EBV-associated malignancies such as nasopharyngeal carcinoma. The therapy involves engineering a patient's own T cells to express a specific T-cell receptor that recognizes EBNA1 peptides presented by MHC molecules on the surface of tumor cells, leading to targeted cell lysis. This approach leverages the company's SUPER TCR-T platform to provide a precision immunotherapy option for patients with EBV-positive solid tumors.

Other names

EBNA1-specific TCR-TEBNA-1-specific TCR-TEBNA 1-specific TCR-TEBV EBNA1-TCR-T cell therapyEpstein-Barr virus nuclear antigen 1 T-cell receptor T-cell therapy